A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 20 Mar 2015
Price : $35 *
At a glance
- Drugs Loteprednol etabonate (Primary) ; Ciclosporin
- Indications Dry eyes
- Focus Therapeutic Use
- 17 Mar 2015 Planned End Date changed from 1 Jun 2014 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
- 17 Mar 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 05 Feb 2014 New trial record